Immunome (IMNM) EBIAT: 2023-2025
Historic EBIAT for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to -$57.5 million.
- Immunome's EBIAT fell 21.99% to -$57.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$222.7 million, marking a year-over-year increase of 27.05%. This contributed to the annual value of -$293.0 million for FY2024, which is 174.29% down from last year.
- Per Immunome's latest filing, its EBIAT stood at -$57.5 million for Q3 2025, which was down 32.40% from -$43.4 million recorded in Q2 2025.
- In the past 5 years, Immunome's EBIAT ranged from a high of -$4.3 million in Q1 2023 and a low of -$129.5 million during Q1 2024.
- Over the past 3 years, Immunome's median EBIAT value was -$43.4 million (recorded in 2025), while the average stood at -$49.3 million.
- Its EBIAT has fluctuated over the past 5 years, first crashed by 2,932.60% in 2024, then spiked by 67.84% in 2025.
- Over the past 3 years, Immunome's EBIAT (Quarterly) stood at -$92.6 million in 2023, then grew by 13.37% to -$80.2 million in 2024, then decreased by 21.99% to -$57.5 million in 2025.
- Its EBIAT stands at -$57.5 million for Q3 2025, versus -$43.4 million for Q2 2025 and -$41.6 million for Q1 2025.